Who Else Wants To Learn The Way To Make It To The Galunisertib Top Spot

In HBe(?) patients a 24?week post treatment sustained response (HBV DNA http://www.selleckchem.com/products/sch772984.html studies [36, 37]. HBeAg seroconversion was observed in 32% of HBeAg(+) patients [36] and HBV DNA http://www.selleck.cn/products/ly2157299.html were 62 and 11% in patients with HBsAg ��300?IU/ml and in those with HBsAg >300?IU/ml at 24?weeks of therapy. The authors also showed that patients with a combined response of HBsAg ��300?IU/ml and a decrease ��1 log10?IU/ml at 24?weeks had higher SVR rates than those without the combined response (75% vs 15%), with a PPV and NPV of 75 and 85% respectively. Tangkijvanich et?al. [39] report that baseline HBsAg levels were lower in patients with HBeAg seroconversion at the end of therapy than in non-responders. In the Neptune study [41-43], the highest HBeAg sero-conversion rates were observed in patients with HBsAg levels ��1500?IU/ml at 12 or 24?weeks of therapy with a PPV of 57 or 54% and a NPV of 72 or 76% respectively (Fig.?4). These results confirm those of the phase III PEG-IFN alfa 2a trial [40]. Sonneveld et?al. [42] showed that HBsAg patients who received a combination of PEG-IFN plus lamivudine (LAM) http://www.selleckchem.com/products/dabrafenib-gsk2118436.html had a more pronounced on-treatment decrease than those who received PEG-IFN alone, although the former relapsed. The absence of decline at week 12 had a NPV of 97% for SVR and no chance of HBsAg loss. The study by Lau reported a lower NPV (82%) than the Sonneveld study. The discrepancy between the two studies might be related to the different populations. Indeed, in the study by Sonneveld most of the patients were genotypes A and D while the Lau study included patients with genotypes B and C. It is interesting to note that certain studies have reported a greater decrease in HBsAg levels in patients with HBV genotypes A and B during PEG-IFN therapy [44-48]. These observations were confirmed in the study by Sonneveld et?al. [48] suggesting that response-guided therapy could be used (Fig.?5). The response rate to PEG-IFN therapy is low (